Quit Smoking Drugs Market 2026 surging toward $90.73 billion by 2030

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Quit Smoking Drugs Market Over The 2026–2030 Period?

The market size for quit smoking drugs has experienced rapid expansion in recent years. It is projected to grow from $44.23 billion in 2025 to $50.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The historical period’s growth can be attributed to increasing awareness of smoking hazards, a rising prevalence of smoking-related diseases, the availability of nicotine replacement therapies, government anti-smoking campaigns, and the growth of pharmaceutical manufacturing in emerging markets.

The quit smoking drugs market size is projected to undergo significant expansion in the coming years, reaching $90.73 billion by 2030, with a compound annual growth rate (CAGR) of 15.5%. This anticipated growth during the forecast period is attributable to advancements in digital health solutions, the rising adoption of personalized medicine, the integration of AI in treatment monitoring, the expansion of telemedicine services, and the increasing presence of wearable health monitoring devices. Key trends for the forecast period encompass personalized nicotine replacement therapies, the development of mobile health (mhealth) and smoking cessation apps, telemedicine-driven prescription support, the integration of behavioral therapy with drug therapy, and the utilization of wearable devices for monitoring cravings.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9247&type=smp

Which Economic Or Industry Drivers Are Impacting The Quit Smoking Drugs Market?

The increasing occurrence of smoking addiction is anticipated to boost the expansion of the quit-smoking drug market in the future. Smoking involves the act of inhaling and exhaling the vapors produced by burning plant materials, including tobacco, marijuana, and hashish, among others. Quit smoking drugs serve to diminish the desire to smoke by curbing an individual’s tobacco cravings; these medications are prescribed to manage nicotine withdrawal symptoms, thereby assisting in successfully stopping smoking. For example, data from November 2025 by the OECD (Organisation for Economic Co-operation and Development), a France-based intergovernmental international organization, revealed that 14.8% of individuals aged 15 and over smoked daily in 2023. The highest percentages of daily smokers were recorded in Türkiye, Hungary, and Greece, alongside accession/partner nations Indonesia, Bulgaria, and China, with at least one in four residents smoking daily. In 2023, the average daily smoking rate for men stood at 18.5%, significantly higher than the 11.4% observed for women. Consequently, the increasing incidence of smoking addiction is fueling the expansion of the quit-smoking drug market.

How Is The Quit Smoking Drugs Market Segmented Across Key Categories?

The quit smoking drugs market covered in this report is segmented –

1) By Product: Drug Therapy, E-Cigarettes, Nicotine Inhalers, Nicotine Replacement Therapies, Nicotine Sublingual Tablets

2) By Drug: Varenicline (Chantix), Bupropion (Zyban), Other Drugs

3) By Distribution: Drug Store, Online Pharmacies, Retail Pharmacies

Subsegments:

1) By Drug Therapy: Bupropion (Zyban), Varenicline (Chantix)

2) By E-Cigarettes: Disposable E-Cigarettes, Rechargeable E-Cigarettes, Pod Systems

3) By Nicotine Inhalers: Prescription Inhalers, Over-The-Counter Inhalers

4) By Nicotine Replacement Therapies (NRT): Nicotine Patches, Nicotine Gum, Nicotine Lozenges

5) By Nicotine Sublingual Tablets: Fast-Acting Sublingual Tablets, Extended-Release Sublingual Tablets

Which Upcoming Trends Are Expected To Influence The Quit Smoking Drugs Market?

Leading companies operating within the quit smoking drugs market are prioritizing the creation of innovative formulations and delivery methods, such as generic tablets, to extend their market dominance regionally and secure a competitive advantage. Generic varenicline tablets represent unbranded forms of the medication containing varenicline tartrate; these are bioequivalent to their original branded counterparts and are utilized in treatments aimed at quitting smoking. An illustrative example is Lupin Limited, an India-based pharmaceutical firm, introducing new Varenicline tablets in the United States in January 2024, offered in strengths of 0.5 mg and 1 mg. These particular tablets are the generic equivalents of Chantix tablets (0.5 mg and 1 mg) by PF Prism C.V., prescribed to aid in smoking cessation therapy. Varenicline functions as a partial agonist of the nicotinic acetylcholine receptor, promoting the release of dopamine, which in turn helps to ease withdrawal symptoms and cravings linked to nicotine dependence. This two-pronged approach enables it to diminish the gratifying sensations of smoking while concurrently offering some stimulation to lessen withdrawal impact.

Who Are The Dominant Players Shaping The Quit Smoking Drugs Market Landscape?

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy’s Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG

Read the full quit smoking drugs market report here:

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

What Are The Top-Performing Regions Within The Quit Smoking Drugs Market?

North America was the largest region in the quit smoking drugs market in 2025. The regions covered in the quit smoking drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Quit Smoking Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9247&type=smp

Browse Through More Reports Similar to the Global Quit Smoking Drugs Market 2026, By The Business Research Company

Quit Smoking Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Nicotine Addiction Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/nicotine-addiction-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795